Document Detail

The Role of Fibrate Treatment in Dyslipidemia: An Overview.
MedLine Citation:
PMID:  23317397     Owner:  NLM     Status:  Publisher    
Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major cardiovascular (CV) risk factor. Nuclear receptor peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid metabolism; PPAR ligands are used to treat dyslipidemias. Fibrates have a major impact on TG metabolism as well as on modulating LDL size and subclasses. Fibrates target atherogenic dyslipidemia by increasing plasma HDL-C concentrations and decreasing small dense LDL (sdLDL) particles and TGs, thus contributing to dyslipidemia management, particularly in patients with diabetes (DM) or the metabolic syndrome (MetS). Furthermore, fibrates exert beneficial effects on adipokines, inflammation and oxidative stress as well as neuroprotective properties. However, further studies are needed to define the role of fibrates in the prevention of CV events. We review the effects of fibrates on atherogenic dyslipidemia and CV risk reduction.
Niki Katsiki; Dragana Nikolic; Giuseppe Montalto; Maciej Banach; Dimitri P Mikhailidis; Manfredi Rizzo
Related Documents :
19043647 - The physical functional capacity of frail elderly persons undergoing ambulatory rehabil...
3129597 - Urinary excretion of 3-methylhistidine as an index of protein nutrition in total parent...
18683027 - The influence of children's diet on their cognition and behavior.
1782917 - Nutritional considerations in the variability of plasma cholesterol measurements.
19498247 - [development of fat suppressed three-dimensional t1-weighted image using linear filling...
24006357 - Weight reduction and maintenance with iqp-pv-101: a 12-week randomized controlled study...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-09
Journal Detail:
Title:  Current pharmaceutical design     Volume:  -     ISSN:  1873-4286     ISO Abbreviation:  Curr. Pharm. Des.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Academic Head Dept. of Clinical Biochemistry (Vascular Disease Prevention Clinics) Royal Free Hospital campus, University College London Medical School, University College London (UCL) Pond Street, London NW3 2QG, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Epidemiologic study of molar-incisor hypomineralization in 8-year-old Spanish children.
Next Document:  Ezetimibe Therapy for Dyslipidemia: An Update.